NCT00498979View on ClinicalTrials.gov

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

January 31, 2012

Conditions

Stage IV Melanoma

Interventions

BIOLOGICAL

recombinant interferon alfa-2b

DRUG

cisplatin

recombinant interferon alfa-2b

DRUG

sodium stibogluconate

DRUG

dacarbazine

DRUG

vinblastine

Trial Locations (1)

44195

Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00498979 - Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers | Biotech Hunter | Biotech Hunter